3 Biotech Stocks Falling Like a Knife: Puma Biotechnology, MacroGenics, and Aratana Therapeutics
George Budwell, The Motley Fool - Motley Fool - Mon Apr 14, 1:30PM CDT
Biotech stocks have been in near free-fall the past month, with the iShares Nasdaq Biotechnology Index dropping a noteworthy 15.4%. While this could be part of a general market correction, such a dramatic decline may indicate deeper issues with...
Nasdaq stocks posting largest percentage decreases
AP - Fri Apr 11, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
PolyTherics and MacroGenics Extend Collaboration to Produce Novel Antibody Drug Conjugates
PR Newswire Europe - Fri Apr 11, 5:42AM CDT
LONDON, April 11, 2014 /PRNewswire/ --
3 Stocks Spiking on Unusual Volume
at The Street - Thu Apr 10, 8:28AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
MacroGenics Slumps: MGNX Falls 7.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 7:46AM CDT
MacroGenics saw a big move last session, as the company’s shares fell by nearly 8% on the day.
MacroGenics Presents Pre-Clinical Data Demonstrating Potent Activity With Colorectal Cancer Product Candidate MGD007 at the AACR Annual Meeting
GlobeNewswire - Sun Apr 06, 3:00PM CDT
MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced the presentation of pre-clinical data demonstrating that MGD007, a dual-affinity re-targeting (DART(R)) protein, has potent activity against colorectal cancer cells both in vitro and in vivo. The data were presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.
MacroGenics to Present at the 13th Annual Needham Healthcare Conference
GlobeNewswire - Tue Apr 01, 7:01AM CDT
MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that Jim Karrels, Vice President and Chief Financial Officer, and Eric Risser, Vice President of Business Development, will present at the 13 Annual Needham Healthcare Conference. The presentation will take place Tuesday, April 8, 2014, at 5:00 p.m. Eastern Time in New York.
MacroGenics to Present Pre-clinical Data on MGD007 at the AACR Annual Meeting
GlobeNewswire - Mon Mar 31, 7:29AM CDT
MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that pre-clinical data on its colorectal cancer product candidate, MGD007, will be presented at the 2014 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA. The poster, titled "Development of MGD007, a gpA33 x CD3 bi-specific DART for T-cell immunotherapy of metastatic colorectal cancer," will be presented Sunday, April 6, 2014, from 1:00-5:00pm PT in Hall A-E, poster section 28, poster number 26.
MacroGenics Provides Update on Corporate Progress and 2013 Financial Results
GlobeNewswire - Thu Mar 20, 3:12PM CDT
-- Six Immuno-Oncology Clinical Programs Projected by End of 2015 --
MacroGenics Announces Date of Year End 2013 Financial Results Conference Call
GlobeNewswire - Thu Mar 13, 3:40PM CDT
MacroGenics, Inc. (Nasdaq:MGNX) today announced that on Thursday, March 20, 2014, the Company will release its financial results for the year ended December 31, 2013. The Company's management team will host a conference call discussing the Company's financial results and recent developments on Thursday, March 20, 2014 at 4:30 pm (EDT). The call can be accessed by dialing (877) 303-6253 (domestic) or (973) 409-9610 (international) five minutes prior to the start of the call and providing the passcode 8248481.
MacroGenics Appoints Matthew Fust to Its Board of Directors
GlobeNewswire - Thu Mar 06, 6:09AM CST
MacroGenics, Inc. (Nasdaq:MGNX) today announced that its Board of Directors is increasing its size from seven to eight members and that Matthew Fust has been appointed to fill the vacancy. Mr. Fust joins the Board and becomes Chairman of its Audit Committee, effective immediately. Mr. Fust will serve as a Class II Director, with Class II having a term expiring at the annual meeting of stockholders to be held in 2015.
MacroGenics to Present at the 26th Annual ROTH Conference
GlobeNewswire - Mon Mar 03, 4:30PM CST
MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that Jon Wigginton, M.D., Senior Vice President, Clinical Development and Jim Karrels, Vice President and Chief Financial Officer, of MacroGenics, are scheduled to present at the 26th Annual ROTH Conference on Monday, March 10, at 10:30 a.m. Pacific (1:30 p.m. Eastern Time).
Nasdaq stocks posting largest volume increases
AP - Thu Feb 13, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading: